This now constitutes the second GLP1R agonist registered for body weight management, as liraglutide 3 mg was approved by the FDA in 2014 for treatment of adult obesity and in 2020 for obesity in adolescents aged 12–17 years (see Related links). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.